Holen Sie sich die Stockscreener-App
63.82
9.36%
-6.59
Handel nachbörslich:
63.75
-0.07
-0.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$70.41
Offen:
$65.9
24-Stunden-Volumen:
4.63M
Relative Volume:
3.74
Marktkapitalisierung:
$7.19B
Einnahmen:
$1.64B
Nettoeinkommen (Verlust:
$121.85M
KGV:
41.44
EPS:
1.54
Netto-Cashflow:
$-480.40M
1W Leistung:
-16.39%
1M Leistung:
-40.22%
6M Leistung:
-48.90%
1J Leistung:
-50.70%
1-Tages-Spanne:
$62.50
$67.47
1-Wochen-Bereich:
$62.50
$76.26
52-Wochen-Spanne:
$62.50
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie SRPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
63.82 | 7.19B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 34.95B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph
Sarepta's Aggressive Growth: 39 New Hires Receive Substantial Equity Package - Stock Titan
Top vaccine official’s ouster sends biotech stocks tumbling - The Boston Globe
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Why Sarepta Therapeutics (SRPT) Stock Is Nosediving - Yahoo Finance
Moderna Stock Sinks After Top FDA Official Resigns; Sarepta Gets Hit, Too. - MSN
RBC Capital Downgrades Sarepta Therapeutics (BMV:SRPT) - Nasdaq
Sarepta downgraded at RBC Capital on gene therapy concerns (SRPT:NASDAQ) - Seeking Alpha
Fiery Resignation of Top FDA Official Sparks Biotech Stock Selloff - Barron's
Sarepta Craters After RBC’s 45% Price Target Cut - Wall Street Pit
Drugmakers tumble on reports FDA's top vaccine regulator set to leave - MarketScreener
A recent gene therapy death shines a light on AAV safety - PharmaVoice
Biotech stocks tumble on reports FDA's top vaccine regulator to leave - MarketScreener
RBC Downgrades Sarepta Therapeutics to Sector Perform From Outperform, Adjusts PT to $87 From $161 - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph
Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy? - Yahoo Finance
Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday? - MSN
Dravet Gene Therapy Tested in Mice, Sarepta’s Setback, and AstraZeneca Updates - Genetic Engineering & Biotechnology News
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Safety Questions Loom in Duchenne as Dyne, Wave and Others Plan FDA Filings - BioSpace
Wave Aspires To Accelerated Approval In DMD With 48-Week Data - News & Insights
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Wave strengthens case for accelerated approval, with more positive Duchenne data - Endpoints News
Sarepta stock plunges to 52-week low, touches $73 By Investing.com - Investing.com South Africa
Sarepta stock plunges to 52-week low, touches $73 - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect - Markets Insider
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion - Nasdaq
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Is This Stock a Buy After a Massive 20% Drop in 1 Day? - Yahoo Finance
StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta - Genetic Engineering & Biotechnology News
PNC Financial Services Group Inc. Has $352,000 Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Scotiabank Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up - NewsBreak: Local News & Alerts
Nvidia, Nike, Sarepta Therapeutics, Protalix and more analyst calls of the week - Proactive Investors UK
This Is What Whales Are Betting On Sarepta Therapeutics - Benzinga
Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing - News & Insights
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Givi - Asianet Newsable
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 4% After Analyst Downgrade - Defense World
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance
HC Wainwright Reiterates “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT) - Defense World
Sarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT) - Defense World
Sarepta plunges after death linked to Elevidys (update) - MSN
Sarepta: Should Investors Run For The Exit? (NASDAQ:SRPT) - Seeking Alpha
Sarepta Therapeutics’ stock falls after patient dies of liver failure - MSN
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More - Zacks Investment Research
Regenxbio Rises After Duchenne Update And Sarepta Safety Scare - News & Insights
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation - Markets Insider
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):